A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone
| Autor: | Ashish Gautam, Nikhil Pursnani, Apoorva Jain, Maaz Farooqui, Prabhat Agrawal, Ashwini Kumar Nigam |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Population Adverse drug reaction lcsh:Medicine 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Diabetes mellitus Internal medicine medicine pioglitazone 030212 general & internal medicine education lcsh:R5-920 education.field_of_study urinary bladder cancer Bladder cancer oral hypoglycemic medicine.diagnostic_test diabetes business.industry Cumulative dose lcsh:R Retrospective cohort study General Medicine Cystoscopy medicine.disease Original Article lcsh:Medicine (General) business Pioglitazone medicine.drug |
| Zdroj: | Perspectives in Clinical Research Perspectives in Clinical Research, Vol 12, Iss 1, Pp 9-13 (2021) |
| ISSN: | 2229-5488 2229-3485 |
| Popis: | Introduction: Pioglitazone has been a cornerstone of oral hypoglycemic therapy. Concerns have been raised about its association with urinary bladder cancer. Considering the wide usage of this drug, concrete and multiple population-based studies are needed to establish the safety of this drug. The present retrospective study is aimed to assess the association of pioglitazone with urinary bladder cancer. Materials and Methods: Clinical records of 4170 patients (2085 pioglitazone users and similar number of nonpioglitazone users) attending the diabetes clinic at a tertiary level teaching hospital were accessed, and the patients were subjected to symptom-directed questionnaire, urine examination, and cystoscopy and bladder biopsy (whenever clinically indicated). The risk of bladder cancer was also assessed with respect to cumulative dose and duration of pioglitazone. Results: We did not observe any increased risk of bladder malignancy with pioglitazone exposure; furthermore, there was no association with cumulative dose and duration of pioglitazone therapy. Pioglitazone was found to be effective and safe in managing glycemic control in diabetic patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|